Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Multimodal Treatment for Resectable Esophageal Cancer by Detecting Minimal Residual Disease Using Circulating Tumor DNA: a Multicentric Prospective Study

NCT05704530 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT05704530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05704530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Multimodal Treatment for Resectable Esophageal Cancer by Detecting Minimal Residual Disease Using Circulating Tumor DNA: a Multicentric Prospective Study
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Not applicable
Overall status
Recruiting
Start date
March 29, 2023
Completion date
December 31, 2029
Enrollment
248 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer